05 Compliance

Where nattokinase is permitted, and what the file must show

Technical document 05 · Reviewed 2026-11-19 · Nattokinase

On this page
  1. Four checks, not one
  2. European Union
  3. United States
  4. United Kingdom
  5. Contaminant limits
  6. Label and claim boundaries
  7. The file a brand should hold
  8. A checklist before the first shipment

Nattokinase sits between two EU regimes: it is a food enzyme, and a nattokinase-containing fermented soybean extract is an authorised novel food. The US asks a different question, and the UK applies a retained framework. The file must show the route, preparation, soy allergen and claims boundary, not only the CAS number.

In one line

Nattokinase is permitted through different routes in the EU, the US and the UK, and the file has to show the preparation and the route, not the name.

Four checks, not one

First, may the preparation be used in the intended market? Second, is the specification covered? Third, do the contaminants sit under the ceiling? Fourth, what may the label and claim say? Answering the first leaves three open.

“Nattokinase” is not one regulated article. It is an activity that can sit in different preparations, from a high-activity powder to an extract on a carrier. A permission for one preparation does not automatically cover another, so read the specification against the entry.

European Union

Regulation (EC) No 1332/2008 is the food-enzyme framework: an enzyme must be covered by the Union list before sale or use, and the list is built in stages, so national provisions can still govern a use. “Nattokinase is permitted in the EU” is too coarse.

The supplement route is Regulation (EU) 2015/2283. The fermented soybean extract was authorised by Commission Implementing Decision (EU) 2017/115 and is now in the Union list under Commission Implementing Regulation (EU) 2017/2470.

The EU novel-food entry beside the catalog specification
ParameterEU entry for fermented soybean extractCatalog nattokinase powder
Preparation30% extract plus 70% resistant dextrin; vitamin K2 removedNattokinase powder, 40 mesh, no carrier declared
Activity20,000–28,000 FU/g≥20,000 FU/g
Loss on drying≤10%≤8.0%
Vitamin K2≤0.1 mg/kg—
Heavy metalsHeavy metals ≤20 · Pb ≤5 · As ≤3 mg/kgPb ≤3 · As ≤2 · Cd ≤1 · Hg ≤0.1 mg/kg
MicrobiologyAPC ≤1,000; yeast and mould ≤100; coliforms ≤30; spore-forming ≤10 cfu/g; E. coli, Salmonella and Listeria absent/25 gAPC ≤10,000; yeast and mould ≤100 cfu/g; E. coli and Salmonella absent
Permitted useSupplements, capsules/tablets/powder; adults excluding pregnant and lactating women; ≤100 mg/dayNot stated in the catalog
Label“Fermented soybean extract”; medical supervision statementNot stated in the catalog

That entry is preparation-specific. The catalog material is a nattokinase powder at ≥20,000 FU/g, not the 30/70 extract, so they are not automatically the same article. The file must map the specification to the entry, or establish another route. Labelling follows Regulation (EU) No 1169/2011 and Directive 2002/46/EC, and soy is an Annex II allergen. For that preparation, the label must also state that persons taking medication should only consume the product under medical supervision.

United States

There is no premarket approval list for nattokinase as a dietary ingredient. The route is DSHEA: use before 15 October 1994, a new dietary ingredient notification at least 75 days before marketing, or a GRAS conclusion for the preparation and use. A GRAS conclusion is company- and use-specific; it does not transfer with the name.

The finished supplement is made under 21 CFR 111, and the Supplement Facts panel follows 21 CFR 101.36. An enzyme activity has no Daily Value, so it does not belong in the nutrition panel; it lives in the specification and certificate. A structure/function statement needs substantiation and the DSHEA disclaimer, and a disease claim is not permitted.

Soy is a major food allergen, so the source is declared under FALCPA. No federal maximum applies to lead, cadmium or mercury in supplements; California Proposition 65 sets warning thresholds, and USP <2232> is a reference some buyers require. The catalog limits are release gates, not a federal ceiling.

United Kingdom

Great Britain applies a retained novel-food and food-enzyme framework. The fermented soybean extract authorisation is the reference for the same preparation, with the 100 mg/day cap and adult population condition; check the GB register before shipping. Northern Ireland follows the EU Union list under the Windsor Framework, so one UK label may not work in all four nations.

Supplement rules are the Food Supplements (England) Regulations 2003 and devolved equivalents, with labelling under the Food Information Regulations 2014 and retained Regulation (EC) No 1924/2006. Soy remains an allergen, and the claims boundary is the same: no disease claim, and no health claim unless authorised.

Contaminant limits

Heavy metals · catalog limits and regulatory ceilings
MetalCatalog limitEU supplement ceilingEU novel-food entryUS federal
Lead (Pb)≤3 mg/kg3.0 mg/kg≤5 mg/kgNo maximum
Arsenic (As)≤2 mg/kgNo harmonised limit≤3 mg/kgNo maximum
Cadmium (Cd)≤1 mg/kg1.0 mg/kg—No maximum
Mercury (Hg)≤0.1 mg/kg0.10 mg/kg—No maximum

EU supplement ceilings are in Regulation (EU) 2023/915; GB retains Regulation (EC) No 1881/2006. The novel-food entry also carries a heavy-metals limit of 20 mg/kg. Compare on the same basis: a result per kilogram of powder and a daily-dose limit differ.

Label and claim boundaries

Nattokinase activity is a quality parameter, not a health claim. As of this review the EU register of authorised health claims has no claim for nattokinase, so a label cannot invent one or borrow another ingredient's. The medical supervision statement is a regulatory warning, not a claim.

In the US, a structure/function statement needs the evidence file and the DSHEA disclaimer, and a disease claim is not permitted. In the EU and UK only authorised health claims may be used. The soy allergen declaration is a safety statement, not optional; the activity belongs on the specification and certificate, not the nutrition panel.

The file a brand should hold

  • Specification naming the source, the strain, the activity and its method, the carrier and the limits.
  • Batch COA with the FU/g result, method, as-is basis, pH, loss on drying, mesh, metals and micro.
  • Technical data sheet and safety data sheet, with the source and activity on both.
  • Novel-food reference and a mapping of the preparation to the entry, or the alternative route.
  • US dietary-ingredient basis: NDI notification, pre-1994 history, or GRAS conclusion for the preparation.
  • Soy allergen, GMO, origin and carrier statements, plus contaminant results with methods.
  • Stability summary, the storage statement and the approved artwork.

A checklist before the first shipment

  1. Does the specification name Bacillus subtilis natto, the strain, the activity and the assay method?
  2. Is the preparation the one covered by the novel-food entry, or is another route documented?
  3. Is the activity reported on an as-is basis with the loss-on-drying result beside it?
  4. Do the metal results meet the destination's limits on the same basis?
  5. Is the soy allergen declared, with the source and carrier statements in the file?
  6. Does the label carry the required designation and the medical supervision statement where it applies?
  7. Is every claim authorised, or absent?
  8. Do the lot codes match on COA, pack and packing list?

The market frameworks are on the EU, US and UK regulatory pages. The COA page breaks the certificate down, the identity page covers source and protein, and the product page carries the catalog limits.

Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.

Request a quotation